CBAI...Jetzt geht es so richtig los!!! - 500 Beiträge pro Seite
eröffnet am 11.05.11 16:18:08 von
neuester Beitrag 07.02.12 07:29:47 von
neuester Beitrag 07.02.12 07:29:47 von
Beiträge: 50
ID: 1.166.109
ID: 1.166.109
Aufrufe heute: 0
Gesamt: 3.613
Gesamt: 3.613
Aktive User: 0
ISIN: US12482D1037 · WKN: A2JM3A
0,0078
USD
+4,00 %
+0,0003 USD
Letzter Kurs 01.07.20 Nasdaq OTC
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6868 | +24,85 | |
| 370,00 | +17,05 | |
| 12,000 | +15,50 | |
| 3,1800 | +15,22 | |
| 1,3200 | +14,78 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,8200 | -11,18 | |
| 1,8700 | -11,79 | |
| 0,5925 | -15,36 | |
| 0,5680 | -18,86 | |
| 399,40 | -22,28 |
Feedback
wollen wir hier weitermachen???
Antwort auf Beitrag Nr.: 41.486.215 von Rioluihui am 11.05.11 16:18:08Wie viel Aktie hat CBAI jetzt?
Antwort auf Beitrag Nr.: 41.490.651 von Scania01 am 12.05.11 11:34:5668 Mio.
************************************
Cord Blood America Reduces "Afford-A-Cord" Program Charges; New Buyers Anticipated
LAS VEGAS, May 12, 2011 /PRNewswire via COMTEX/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC BB: CBAID), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it is reducing the monthly payment in its unique "Afford-A-Cord" storage program from $29 a month to $19.
Afford-A-Cord reduces the initial cost of storing umbilical cord blood stem cells from $2075 to $495 plus medical courier service. The Afford-A-Cord program is offered as an additional payment option to the Company's long standing traditional payment programs. It accounted for four percent of the Company's revenues in the most recent fiscal year.
"The data tells the story. It was four percent of our revenues, and without a doubt, these families would otherwise not have bought cord blood storage at all. The Afford-A-Cord program is strictly designed to bring in new buyers that historically could not afford to store stem cells. By reducing the monthly fee even further, our expectation is that this program will become an even greater portion of our business portfolio," said Matthew Schissler, Cord Blood America co-founder and CEO.
"Parents and grandparents who realize the importance of storing a baby's umbilical cord blood stem cells, but who are strapped financially, still should have the opportunity to participate in this potentially live saving program," Mr. Schissler said. "No other company offers such a low entry point, one that will allow a greater number of families to store their child's stem cells and, with the lowering of the monthly fee, we hope to provide this service to more families whose financial situations are difficult in the current economy."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAID) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of diseases, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
SOURCE Cord Blood America, Inc.
www.prnewswire.com
************************************
Cord Blood America Reduces "Afford-A-Cord" Program Charges; New Buyers Anticipated
LAS VEGAS, May 12, 2011 /PRNewswire via COMTEX/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC BB: CBAID), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it is reducing the monthly payment in its unique "Afford-A-Cord" storage program from $29 a month to $19.
Afford-A-Cord reduces the initial cost of storing umbilical cord blood stem cells from $2075 to $495 plus medical courier service. The Afford-A-Cord program is offered as an additional payment option to the Company's long standing traditional payment programs. It accounted for four percent of the Company's revenues in the most recent fiscal year.
"The data tells the story. It was four percent of our revenues, and without a doubt, these families would otherwise not have bought cord blood storage at all. The Afford-A-Cord program is strictly designed to bring in new buyers that historically could not afford to store stem cells. By reducing the monthly fee even further, our expectation is that this program will become an even greater portion of our business portfolio," said Matthew Schissler, Cord Blood America co-founder and CEO.
"Parents and grandparents who realize the importance of storing a baby's umbilical cord blood stem cells, but who are strapped financially, still should have the opportunity to participate in this potentially live saving program," Mr. Schissler said. "No other company offers such a low entry point, one that will allow a greater number of families to store their child's stem cells and, with the lowering of the monthly fee, we hope to provide this service to more families whose financial situations are difficult in the current economy."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAID) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of diseases, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
SOURCE Cord Blood America, Inc.
www.prnewswire.com
Das geht ja hier wirklich richtig los
Antwort auf Beitrag Nr.: 41.495.149 von lilie31 am 12.05.11 22:13:57Warum seh nur ich hier nix, dass es losgeht 
Warum kann man die Aktie in D net mehr handeln?
Warum kann man die Aktie in D net mehr handeln?
Trading Spotlight
Antwort auf Beitrag Nr.: 41.497.187 von djkief am 13.05.11 10:50:30Ich denke wenn ich auch welche unter 0,20kriegen sollte,werde ich auch einsteigen.
Die Aktie ist schon da Angekommen wo die Fähr bewertet ist.
Wenn der CEO wieder kein strich durch die Rechnung macht.
Die Aktie ist schon da Angekommen wo die Fähr bewertet ist.
Wenn der CEO wieder kein strich durch die Rechnung macht.
In meinem Depot ist noch immer nix umgestellt!
Hat noch wer das Problem?
Immer noch die alte Stückzahl und folgende Kennung.
US21839P1075
Kann mir wer weiterhelfen?
Hat noch wer das Problem?
Immer noch die alte Stückzahl und folgende Kennung.
US21839P1075
Kann mir wer weiterhelfen?
Antwort auf Beitrag Nr.: 41.554.050 von zucksn am 25.05.11 12:43:35bei mir genauso. Würde mal behaupten die haben irgendwelche Formalitäten verpennt.
Antwort auf Beitrag Nr.: 41.555.567 von kleingeldjaeger am 25.05.11 16:13:49Bei mir (flatex) auch noch keine Umstellung
Bei mir au noch nix
Geht es nun bald mal los?
Wie soll das gehen wenn die Umsätze so niedrig bleiben.
Oder hat hier einer schon fast den ganzen Aktienbestand aufgekauft?
1 Dollar ich komme.
Wie soll das gehen wenn die Umsätze so niedrig bleiben.
Oder hat hier einer schon fast den ganzen Aktienbestand aufgekauft?
1 Dollar ich komme.
Zitat von Expertchen007: 68 Mio.
************************************
Cord Blood America Reduces "Afford-A-Cord" Program Charges; New Buyers Anticipated
LAS VEGAS, May 12, 2011 /PRNewswire via COMTEX/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC BB: CBAID), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it is reducing the monthly payment in its unique "Afford-A-Cord" storage program from $29 a month to $19.
Afford-A-Cord reduces the initial cost of storing umbilical cord blood stem cells from $2075 to $495 plus medical courier service. The Afford-A-Cord program is offered as an additional payment option to the Company's long standing traditional payment programs. It accounted for four percent of the Company's revenues in the most recent fiscal year.
"The data tells the story. It was four percent of our revenues, and without a doubt, these families would otherwise not have bought cord blood storage at all. The Afford-A-Cord program is strictly designed to bring in new buyers that historically could not afford to store stem cells. By reducing the monthly fee even further, our expectation is that this program will become an even greater portion of our business portfolio," said Matthew Schissler, Cord Blood America co-founder and CEO.
"Parents and grandparents who realize the importance of storing a baby's umbilical cord blood stem cells, but who are strapped financially, still should have the opportunity to participate in this potentially live saving program," Mr. Schissler said. "No other company offers such a low entry point, one that will allow a greater number of families to store their child's stem cells and, with the lowering of the monthly fee, we hope to provide this service to more families whose financial situations are difficult in the current economy."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAID) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of diseases, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
SOURCE Cord Blood America, Inc.
www.prnewswire.com
Number of shares of Cord Blood America, Inc. common stock, $0.0001 par value, outstanding as of September 30, 2011, 101,018,608 exclusive of treasury shares.
www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8238092
Bei einen Gewinn pro Aktie von 0,05 und einen KGV 20, sind
1 Dollar durch aus drin. Muss CBAI bloß noch etwas Gas geben.
1 Dollar durch aus drin. Muss CBAI bloß noch etwas Gas geben.
Antwort auf Beitrag Nr.: 42.397.415 von Karpatenaal am 25.11.11 08:31:03Und wie hoch ist der derzeitige Streubesitz?
Antwort auf Beitrag Nr.: 42.404.366 von Scania01 am 27.11.11 09:59:48na jetzt steng mal Deine Birne auch selber etwas an.....
Von denen hatte ich mal 22.000 Stück .......für 0,001 nach der Umstellung jetzt noch 220 ......wie nett wenn die mal auf 1 € gehen sollte ....dann wäre das erste doch ein wenig angenehmer :-)Also vorsichtig mit den Meldungen hier ......die brauchen bestimmt wieder ein bisschen Geld....nur meine Meinung
Antwort auf Beitrag Nr.: 42.408.597 von seb262 am 28.11.11 15:00:11
...22 K zu 0,001 = 22 € Einsatz...na da frag ich mich wo der Sinn liegt.. ??????
Kann dir mal 5 oder 10 Millionen abgeben zu einem guten Preis....gerne .....dann hab ich zwar immer noch min. 70 % Verlust...aber wenigstens ein nettes Wochenende. Eh bereits voll abgeschrieben.
...22 K zu 0,001 = 22 € Einsatz...na da frag ich mich wo der Sinn liegt.. ??????Kann dir mal 5 oder 10 Millionen abgeben zu einem guten Preis....gerne .....dann hab ich zwar immer noch min. 70 % Verlust...aber wenigstens ein nettes Wochenende. Eh bereits voll abgeschrieben.
Antwort auf Beitrag Nr.: 42.408.910 von Expertchen007 am 28.11.11 15:43:02Kommando zurück...war beim falschen Wert was die Menge meinerseits betrifft....
kommt vor bei knapp 40 versch. Werten die zu Händeln sind
kommt vor bei knapp 40 versch. Werten die zu Händeln sind
Antwort auf Beitrag Nr.: 42.407.544 von Expertchen007 am 28.11.11 12:05:22Ich stell ja nicht umsonst eine Frage. Wo kann man das nach lesen?
Oder hast du selber keine Ahnung?
Oder hast du selber keine Ahnung?
Zitat von Scania01: Ich stell ja nicht umsonst eine Frage. Wo kann man das nach lesen?
Oder hast du selber keine Ahnung?
Die Daten gibts gerade - Steubesitz ( Flow ) derzeit keine Angabe....
CBAI Security Details
Share Structure
Market Value1 $3,980,133 a/o Nov 25, 2011
Shares Outstanding 101,018,608 a/o Sep 30, 2011
Float Not Available
Authorized Shares Not Available
Par Value 0.0001
Shareholders
Shareholders of Record 506 a/o Mar 31, 2011
http://www.otcmarkets.com/stock/CBAI/company-info
ansonsten meine ich im Q Bericht was gelesen zu haben....musste mal durchschauen...ich schau morgen mal...leider gerade wenig Zeit.
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=823809…
Antwort auf Beitrag Nr.: 42.410.611 von Expertchen007 am 28.11.11 20:34:00nicht Flow..sondern Float natürlich
vielleicht hilft Dir das weiter.....weitere 148 Mio. sind noch zur Freigabe offen falls nötig.
As of September 30, 2011 CBAI had 101,018,608 shares of Common Stock outstanding. 148,981,392 shares remain in the Company's treasury.
Q bericht Seite 22
ansonsten finde ich auf die Schnelle jetzt auch nichts
vielleicht hilft Dir das weiter.....weitere 148 Mio. sind noch zur Freigabe offen falls nötig.
As of September 30, 2011 CBAI had 101,018,608 shares of Common Stock outstanding. 148,981,392 shares remain in the Company's treasury.
Q bericht Seite 22
ansonsten finde ich auf die Schnelle jetzt auch nichts
Antwort auf Beitrag Nr.: 42.410.640 von Expertchen007 am 28.11.11 20:42:18Keine Panik, hab bei Bloomberg nach gesehen, Streubesitz bei ca. 100 Prozent.
Da es aber meistens alte Daten sind, weis man ja nie ob nicht vielleicht
Warren Bufett seinen Fuß schon bei CBAI drin hat.
So Long............
Da es aber meistens alte Daten sind, weis man ja nie ob nicht vielleicht
Warren Bufett seinen Fuß schon bei CBAI drin hat.
So Long............
Antwort auf Beitrag Nr.: 42.411.180 von Scania01 am 28.11.11 22:25:02wenn er das liest, investiert er bestimmt bald in cbai-aktien:
LAS VEGAS, Sept. 15, 2011 /PRNewswire/ -- Dear Fellow Cord Blood America Shareholders:We receive e-mails, calls or other forms of communications daily concerned about our stock price. We share that concern. Please know that your management teams also are shareholders and seeing the current market value is disappointing to all of us.We are disappointed that the market currently does not recognize the very strong fundamentals of our Company. It does not value our achievements, as it did in previous years passed. We know it is important to continually communicate our positive accomplishments...and I promise to you that we will not quit. Ever.In the last two years we have worked diligently to grow the company. We believe our numbers reflect that effort. Organic growth, acquisitions and diversification of revenue streams have been our mantra. Our credibility was execution on those three, and I feel to a large extent, we achieved that. However the share price does not reflect it, and, ultimately, I vow that we will spend every day working to restore a share price that more accurately reflects the fair value of the Company today, and in the future. I would like to address in this note issues concerning the Present Value of our Company. Frankly, we should be valued well above our current market cap. Yes, all management teams say that, however, our data truly reflects an undervaluation. These are some of the key reasons:* The net present value of our annual storage revenues alone, not including any new business whatsoever, while in a down market is still worth over $11,000,000 and can be argued much higher than this number.* Total revenue due to us over the next 18 years from annual storage agreements alone, again, not inclusive of any new business, estimated to be in excess of $25,000,000* 61% positive revenue growth in first six months of 2011* 100% positive gross profit growth in same time period coupled with ever increasing gross margin percentages* 37% loss reduction in same time period* A strong organic growth engine adding 15 new insurance company contracts in the past 12 months* Tracking towards total revenues of $6,000,000. Domestic sales hit highest levels in an August month since 2007 and trends indicate more positive outcomes for September. We have added 15 new insurance contracts in 2011. While they take time to bear fruit, we are hopeful we are seeing the beginning of this effort. * Cost controls that more closely align revenues with expenditures for all operations. Company anticipates the quarterly narrowing of operational losses in Q3 and Q4 from Q1 and Q2 levels. We saw a normalized market value of $25M consistent for over one year in 2009-2010 for our Company when we were much smaller. We have been active in the acquisition market now for several years, and we can tell you that
A large competitor with worse financials but strong market valuation realized 5x revenues for their company when they exited the market.
Even in distressed situations, companies can receive a minimum of $300 per contract which would put our value at a very minimum over $9M. Again, this is no goodwill or additional component valued for organic growth.
To put it another way, our fundamentals are strong and this Company, truly, has never been in better financial shape. A man I admire, Bill Polian, Vice Chairman of the Indianapolis Colts who has had tremendous success in the NFL for many decades, routinely says, and I'll paraphrase, that "the only thing the team is concerned with is the 53 men on the field and the employees in the building, getting them better, stronger and ready to play weekly. If you focus on the fundamentals, everything else falls into place." I feel the same way: focus on the people at our lab in Las Vegas, our lab in Argentina, our office in Germany, our investments in China and Spain. Focus on our financials, our quality products, diversification of revenues, and healthy organic business. Focus on the fundamentals, and the rest will take care of itself. I'd like to reflect back for a moment on why we started this Company. What we market is similar to an insurance policy, conveying a strong peace of mind. We believed then, and we believe even more today, that stem cells will play a key role in launching a new era of medicine, an era in which we are finally successful against some of the most intractable diseases mankind faces. Cryogenically preserved umbilical cord blood stem cells have already been used to successfully treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. What is so amazing is that in laboratories across our globe stem cells are being studied for use against stroke, spinal cord injuries, heart disease, Parkinson's disease, multiple sclerosis, diabetes and almost any disease you can name which now cannot be cured. One breakthrough in one of these laboratories is going to make stem cells one of the hottest sectors in the entire market, of that I am convinced. Researchers dream that the cells they remove from umbilical cord blood can someday be turned into any single tissue in the body, allowing for the repair of a damaged heart or a brain ravaged by a stroke. Has this been a difficult period? Yes. Every company that grew from an idea at the kitchen table to a power in its sector has had difficult periods. But I want to make this promise clear to our shareholders: We will not quit. We will work every day to improve the quality of the Company, confident that someday this will be recognized by the marketplace. For those of you who have stuck with us for years, our heartfelt thanks. We recognize many of you have followed our news and are looking for more. During the time of undervaluation, our focus is fundamentals. The news will come, it always has. Better to be opportunistic than to force action. Please know the sweat equity we pour into this company every day to someday realize the true valuation of our growing business. Sincerely,Matthew L. SchisslerChairman, Co-Founder and CEOForward-Looking StatementsSome statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.About Cord Blood AmericaCord Blood America (OTC Bulletin Board:CBAI.ob - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.CONTACT:Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com
http://finance.yahoo.com/news/Cord-Blood-America-CEO-prnews-…
LAS VEGAS, Sept. 15, 2011 /PRNewswire/ -- Dear Fellow Cord Blood America Shareholders:We receive e-mails, calls or other forms of communications daily concerned about our stock price. We share that concern. Please know that your management teams also are shareholders and seeing the current market value is disappointing to all of us.We are disappointed that the market currently does not recognize the very strong fundamentals of our Company. It does not value our achievements, as it did in previous years passed. We know it is important to continually communicate our positive accomplishments...and I promise to you that we will not quit. Ever.In the last two years we have worked diligently to grow the company. We believe our numbers reflect that effort. Organic growth, acquisitions and diversification of revenue streams have been our mantra. Our credibility was execution on those three, and I feel to a large extent, we achieved that. However the share price does not reflect it, and, ultimately, I vow that we will spend every day working to restore a share price that more accurately reflects the fair value of the Company today, and in the future. I would like to address in this note issues concerning the Present Value of our Company. Frankly, we should be valued well above our current market cap. Yes, all management teams say that, however, our data truly reflects an undervaluation. These are some of the key reasons:* The net present value of our annual storage revenues alone, not including any new business whatsoever, while in a down market is still worth over $11,000,000 and can be argued much higher than this number.* Total revenue due to us over the next 18 years from annual storage agreements alone, again, not inclusive of any new business, estimated to be in excess of $25,000,000* 61% positive revenue growth in first six months of 2011* 100% positive gross profit growth in same time period coupled with ever increasing gross margin percentages* 37% loss reduction in same time period* A strong organic growth engine adding 15 new insurance company contracts in the past 12 months* Tracking towards total revenues of $6,000,000. Domestic sales hit highest levels in an August month since 2007 and trends indicate more positive outcomes for September. We have added 15 new insurance contracts in 2011. While they take time to bear fruit, we are hopeful we are seeing the beginning of this effort. * Cost controls that more closely align revenues with expenditures for all operations. Company anticipates the quarterly narrowing of operational losses in Q3 and Q4 from Q1 and Q2 levels. We saw a normalized market value of $25M consistent for over one year in 2009-2010 for our Company when we were much smaller. We have been active in the acquisition market now for several years, and we can tell you that
A large competitor with worse financials but strong market valuation realized 5x revenues for their company when they exited the market.
Even in distressed situations, companies can receive a minimum of $300 per contract which would put our value at a very minimum over $9M. Again, this is no goodwill or additional component valued for organic growth.
To put it another way, our fundamentals are strong and this Company, truly, has never been in better financial shape. A man I admire, Bill Polian, Vice Chairman of the Indianapolis Colts who has had tremendous success in the NFL for many decades, routinely says, and I'll paraphrase, that "the only thing the team is concerned with is the 53 men on the field and the employees in the building, getting them better, stronger and ready to play weekly. If you focus on the fundamentals, everything else falls into place." I feel the same way: focus on the people at our lab in Las Vegas, our lab in Argentina, our office in Germany, our investments in China and Spain. Focus on our financials, our quality products, diversification of revenues, and healthy organic business. Focus on the fundamentals, and the rest will take care of itself. I'd like to reflect back for a moment on why we started this Company. What we market is similar to an insurance policy, conveying a strong peace of mind. We believed then, and we believe even more today, that stem cells will play a key role in launching a new era of medicine, an era in which we are finally successful against some of the most intractable diseases mankind faces. Cryogenically preserved umbilical cord blood stem cells have already been used to successfully treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. What is so amazing is that in laboratories across our globe stem cells are being studied for use against stroke, spinal cord injuries, heart disease, Parkinson's disease, multiple sclerosis, diabetes and almost any disease you can name which now cannot be cured. One breakthrough in one of these laboratories is going to make stem cells one of the hottest sectors in the entire market, of that I am convinced. Researchers dream that the cells they remove from umbilical cord blood can someday be turned into any single tissue in the body, allowing for the repair of a damaged heart or a brain ravaged by a stroke. Has this been a difficult period? Yes. Every company that grew from an idea at the kitchen table to a power in its sector has had difficult periods. But I want to make this promise clear to our shareholders: We will not quit. We will work every day to improve the quality of the Company, confident that someday this will be recognized by the marketplace. For those of you who have stuck with us for years, our heartfelt thanks. We recognize many of you have followed our news and are looking for more. During the time of undervaluation, our focus is fundamentals. The news will come, it always has. Better to be opportunistic than to force action. Please know the sweat equity we pour into this company every day to someday realize the true valuation of our growing business. Sincerely,Matthew L. SchisslerChairman, Co-Founder and CEOForward-Looking StatementsSome statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.About Cord Blood AmericaCord Blood America (OTC Bulletin Board:CBAI.ob - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.CONTACT:Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com
http://finance.yahoo.com/news/Cord-Blood-America-CEO-prnews-…
In den USA könnte der Boden erreicht sein!!!
Lege mich fest:
Boden bei 0.025 Cent!
In den USA gehen sie von einem Jahresendspurt bis auf 8 Cent aus.
Dazu zu Info:
Quarterly:
Gross Revenue 3/2010 $839,000 (+30.5%)
Gross Revenue 6/2010 $952,000 (+13.5%)
Gross Revenue 9/2010 $958,449 (+0.7%)
Gross Revenue 12/2010 $1,379,000 (+43.9%)
Gross Revenue 3/2011 $1,457,912 (+5.7%)
Gross Revenue 6/2011 $1,430,000 (-1.9%)
Gross Revenue 9/2011 $1,493,000 (+4.4%)
Cost of Revenue 3/2010 $415,000 (-14.8%)
Cost of Revenue 6/2010 $401,000 (-3.4%)
Cost of Revenue 9/2010 $355,790 (-11.3%)
Cost of Revenue 12/2010 $450,000 (+26.5%)
Cost of Revenue 3/2011 $471,202 (+4.7%)
Cost of Revenue 6/2011 $460,000 (-2.4%)
Cost of Revenue 9/2011 $437,000 (-5.0%)
Net Revenue 3/2010 $424,000 (+171.8%)
Net Revenue 6/2010 $551,000 (+30.0%)
Net Revenue 9/2010 $602,659 (+9.4%)
Net Revenue 12/2010 $929,000 (+54.2%)
Net Revenue 3/2011 $986,710 (+6.2%)
Net Revenue 6/2011 $970,000 (-1.7%)
Net Revenue 9/2011 $1,056,000 (+8.9%)
Operating Exp 3/2010 $2,570,000 (-34.3%)
Operating Exp 6/2010 $2,035,000 (-20.8%)
Operating Exp 9/2010 $2,361,878 (+16.1%)
Operating Exp 12/2010 $2,211,000 (-6.4%)
Operating Exp 3/2011 $2,130,554 (-3.6%)
Operating Exp 6/2011 $1,877,000 (-11.9%)
Operating Exp 9/2011 $1,550,000 (-17.4%)
Loss Fr. Ops 3/2010 $2,146,756 (+$1,699,244)
Loss Fr. Ops 6/2010 $1,579,000 (+$567,756)
Loss Fr. Ops 9/2010 $1,759,219 (-$180,216)
Loss Fr. Ops 12/2010 $1,282,000 (+$477,219)
Loss Fr. Ops 3/2011 $1,438,844 (-$156,844)
Loss Fr. Ops 6/2011 $611,000 (+$827,000)
Loss Fr. Ops 9/2011 $494,000 (+$117,000)
Sentiment : Strong Buy
Boden bei 0.025 Cent!
In den USA gehen sie von einem Jahresendspurt bis auf 8 Cent aus.
Dazu zu Info:
Quarterly:
Gross Revenue 3/2010 $839,000 (+30.5%)
Gross Revenue 6/2010 $952,000 (+13.5%)
Gross Revenue 9/2010 $958,449 (+0.7%)
Gross Revenue 12/2010 $1,379,000 (+43.9%)
Gross Revenue 3/2011 $1,457,912 (+5.7%)
Gross Revenue 6/2011 $1,430,000 (-1.9%)
Gross Revenue 9/2011 $1,493,000 (+4.4%)
Cost of Revenue 3/2010 $415,000 (-14.8%)
Cost of Revenue 6/2010 $401,000 (-3.4%)
Cost of Revenue 9/2010 $355,790 (-11.3%)
Cost of Revenue 12/2010 $450,000 (+26.5%)
Cost of Revenue 3/2011 $471,202 (+4.7%)
Cost of Revenue 6/2011 $460,000 (-2.4%)
Cost of Revenue 9/2011 $437,000 (-5.0%)
Net Revenue 3/2010 $424,000 (+171.8%)
Net Revenue 6/2010 $551,000 (+30.0%)
Net Revenue 9/2010 $602,659 (+9.4%)
Net Revenue 12/2010 $929,000 (+54.2%)
Net Revenue 3/2011 $986,710 (+6.2%)
Net Revenue 6/2011 $970,000 (-1.7%)
Net Revenue 9/2011 $1,056,000 (+8.9%)
Operating Exp 3/2010 $2,570,000 (-34.3%)
Operating Exp 6/2010 $2,035,000 (-20.8%)
Operating Exp 9/2010 $2,361,878 (+16.1%)
Operating Exp 12/2010 $2,211,000 (-6.4%)
Operating Exp 3/2011 $2,130,554 (-3.6%)
Operating Exp 6/2011 $1,877,000 (-11.9%)
Operating Exp 9/2011 $1,550,000 (-17.4%)
Loss Fr. Ops 3/2010 $2,146,756 (+$1,699,244)
Loss Fr. Ops 6/2010 $1,579,000 (+$567,756)
Loss Fr. Ops 9/2010 $1,759,219 (-$180,216)
Loss Fr. Ops 12/2010 $1,282,000 (+$477,219)
Loss Fr. Ops 3/2011 $1,438,844 (-$156,844)
Loss Fr. Ops 6/2011 $611,000 (+$827,000)
Loss Fr. Ops 9/2011 $494,000 (+$117,000)
Sentiment : Strong Buy
Auf dem graumarkt in den USA schon zweistellig im Plus.
Sensationelles Interview vom CEO:
Was für Aussichten!!!
http://finance.yahoo.com/news/Cord-Blood-America-CEO-prnews-…
Sensationelles Interview vom CEO:
Was für Aussichten!!!
http://finance.yahoo.com/news/Cord-Blood-America-CEO-prnews-…
!
Dieser Beitrag wurde von akummermehr moderiert. Grund: keine Quelle
Antwort auf Beitrag Nr.: 42.494.109 von stephan101010 am 17.12.11 08:48:21Wo bitte steht das? Mal eine Quelle dazu angeben.
Macht doch gar keinen Sinn zur Zeit.
Macht doch gar keinen Sinn zur Zeit.
!
Dieser Beitrag wurde von akummermehr moderiert. Grund: Korrespondierendes Posting wurde entfernt
da hilft nur eins: SCHREIBVERBOT!!!!!!
@ all:
den stephan bitte nicht ernst nehmen !!! der schreibt des öfteren wirres zeug !!!!
vielleicht sollte wo ihn mal sperren, damit er nicht mehr so einen blödsinn schreiben kann !!!!!
den stephan bitte nicht ernst nehmen !!! der schreibt des öfteren wirres zeug !!!!
vielleicht sollte wo ihn mal sperren, damit er nicht mehr so einen blödsinn schreiben kann !!!!!
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: ohne nachvollziehbare Quellenangabe, unbewiesene Tatsachenbehauptung
Antwort auf Beitrag Nr.: 42.497.080 von stephan101010 am 19.12.11 07:12:31Behauptung ohne entsprechenden Beleg / Verweis. Ignorieren.
Ich bin mal gespannt wann hier was los geht. Der Chart sieht vielversprechend aus. 2012 könnte ein RaktenStartjahr werden.
Antwort auf Beitrag Nr.: 42.537.178 von Scania01 am 01.01.12 17:20:57schreibs den gleichen Schmarn wie in 2011 auch...nicht nur hier...wir Anleger und Mitaufbauer/Altinvestoren von CORD Blood...haben hier alle rund 99,9 % unseres Kapitals verloren...( der Chart zeigt DOLLAR an und nicht etwas Cent )
Genau, wir sind mit CBAI voll auf die Fresse geflogen.Wenn wirklich noch jemand glaubt, hier gibt es was zu holen, der wird schnell feststellen, was für eine Schrottaktie CBAI ist. Vor dem RE-Splitt hatten wir ja wenigstens das 1000-fache an Aktien und man konnte hoffen, dass es vielleicht mal bergauf geht.Aber jetzt. Am besten den Schrott ausbuchen lassen. Der Einzige, der hier was mit seiner Konkursbude holt, ist Schissler oder wie der Betrüger heißt. Am besten Einsperren den Typen.
Antwort auf Beitrag Nr.: 42.539.182 von Expertchen007 am 02.01.12 14:26:22Die ganzen Jahre gepusht und nun nach RS und der Kurs unten liegt wird gebasht.
Wir sind aber nicht hier bei Genta wo es anscheinend kein Boden gibt.
Hier wird auch was erwirtschaftet.
Wir sind aber nicht hier bei Genta wo es anscheinend kein Boden gibt.
Hier wird auch was erwirtschaftet.
Wer noch 26 Euro Rest hat von ehemals 5000, der kann sich nun darüber freuen das es heute wahrscheinlich nochmal 2 Euro weniger werden.
Die nächsten 32 Millionen Shares:
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…
Die nächsten 32 Millionen Shares:
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…
Zitat von kleingeldjaeger: Wer noch 26 Euro Rest hat von ehemals 5000, der kann sich nun darüber freuen das es heute wahrscheinlich nochmal 2 Euro weniger werden.
Die nächsten 32 Millionen Shares:
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…
jetzt der nächste
- also ich finde nichts
Schade das ich kein Cash mehr hatte... DAs wäre wieder eine Möglichkeit gewesen... Jetzt nur noch ver4-fachen dann bin ich plusminus 0 - machbar oder? 
bei dem Verlust des letzten Jahres ist das alles Pillepalle
bei dem Verlust des letzten Jahres ist das alles Pillepalle
Hab mir heute in Germany mal ein paar zu 20 ins depot gelegt.
Der Artikel ist ja wirklich mal interessant.!!!
Der Artikel ist ja wirklich mal interessant.!!!
Hallo aufwachen, hier wird nur Kapital verbrannt.
Antwort auf Beitrag Nr.: 42.569.495 von JimmySpoon am 09.01.12 17:13:33..und zu 25 wieder raus. Kleinvieh...
Antwort auf Beitrag Nr.: 42.570.095 von JimmySpoon am 09.01.12 19:01:58Glückwunsch,
dann waren das deine 60.000 heute in Stuttgart.
dann waren das deine 60.000 heute in Stuttgart.
Antwort auf Beitrag Nr.: 42.570.095 von JimmySpoon am 09.01.12 19:01:58
Könnte bald wieder richtig los gehen sieht aus wie Boden.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +2,16 | |
| +5,61 | |
| -3,67 | |
| -1,00 | |
| +0,14 | |
| +0,14 | |
| -2,86 | |
| -1,75 | |
| -3,18 | |
| +0,95 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 227 | ||
| 180 | ||
| 94 | ||
| 58 | ||
| 52 | ||
| 47 | ||
| 45 | ||
| 39 | ||
| 38 | ||
| 31 |
